Based on this evidence and beyond, current clinical guidelines recommend 3-year adjuvant imatinib (400 mg daily) for high-risk GIST patients carrying imatinib-sensitive KIT or PDGFRA mutations (25). This evidence concerns the gene KIT and gastrointestinal stromal tumor.